Logo image
In adults at high CV risk and without previous MI or stroke, evolocumab reduced major adverse CV event composites at a median 4.6 y
Journal article   Peer reviewed

In adults at high CV risk and without previous MI or stroke, evolocumab reduced major adverse CV event composites at a median 4.6 y

Anthony Donato and ACP Journal Club Editorial Team at McMaster University
Annals of internal medicine
03 Mar 2026
PMID: 41771125

Abstract

GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Medicine, General & Internal
Logo image